By: IPP Bureau
Last updated : June 13, 2026 8:30 am
MeRT becomes one of the few FDA-cleared neuromodulation therapies for PTSD, using EEG biomarkers and AI to personalize treatment for patients with treatment-resistant symptoms
The US Food and Drug Administration (FDA) has granted clearance to Wave Neuroscience’s precision neuromodulation platform for the treatment of post-traumatic stress disorder (PTSD), marking a significant advancement in personalized mental healthcare.
The clearance allows the company’s magnetic electroencephalogram-guided resonance therapy (MeRT) system to be used for PTSD treatment in the United States.
The platform combines electroencephalogram (EEG)-derived brain activity biomarkers with artificial intelligence (AI) to personalize transcranial magnetic stimulation (TMS) therapy according to an individual patient’s neural activity patterns.
Wave Neuroscience says the technology represents a shift from the traditional “one-size-fits-all” approach to neuromodulation by tailoring treatment based on objective brain activity measurements.
The personalized strategy is particularly relevant for patients with treatment-resistant PTSD who have not responded adequately to conventional interventions such as cognitive behavioural therapy (CBT) or eye movement desensitisation and reprocessing (EMDR).
The FDA decision builds on the breakthrough device designation granted to MeRT in 2024 and was supported by data from the MeRT-005-B clinical trial (NCT02990793).
Conducted in collaboration with investigators at the Texas A&M Health Institute of Biosciences and Technology, the study enrolled 158 patients and demonstrated significant and clinically meaningful reductions in PTSD symptom severity following treatment with the MeRT system.
The clearance positions MeRT among a growing number of FDA-authorized neuromodulation therapies for PTSD. It joins GrayMatter Health’s Prism platform, cleared in 2023, and Neurovalens’ Modius Spero headset, which received FDA clearance in May 2026.
Fred Walke, Chief Executive Officer of Wave Neuroscience, said, “We believe the next era will be defined by precision-based biomarker-guided technologies capable of personalising treatment to the unique neurophysiology of each patient.”
"MeRT was specifically built to lead that transition. FDA clearance for PTSD validates the scientific foundation of our platform and reinforces the growing importance of data-driven, individualised approaches to treating complex neuropsychiatric conditions,” Walke added.